Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021 Oct 18. pii: S0140-6736(21)02188.
PMID: 34672967